Barton, G.R., Bankart, J., Davis, A.C., Summerfield, Q.A.: Comparing utility scores before and after hearing-aid provision: results according to the EQ-5D, HUI3 and SF-6D. Appl. Health Econ. Health Policy 3(2), 103–105 (2004)
Article
Google Scholar
Bharmal, M., Thomas, J. 3rd.: Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9(4), 262–271 (2006)
Article
Google Scholar
Boonen, A., van der Heijde, D., Landewe, R., van Tubergen, A., Mielants, H., Dougados, M., van der Linden, S.: How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann. Rheum. Dis. 66(6), 771–777 (2007)
Article
Google Scholar
Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–292 (2002)
Article
Google Scholar
Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13, 873–884 (2004)
Article
Google Scholar
Bryan, S., Longworth, L.: Measuring health-related utility: why disparity between EQ-5D and SF-6D? Eur. J. Health Econ. 6, 253–260 (2005)
Article
Google Scholar
Dolan, P.: Modelling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)
Article
Google Scholar
Fisk, J.D., Brown, M.G., Sketris, I.S., Metz, L.M., Murray, T.J., Stadnyk, K.J.: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J. Neurol. Neurosurg. Psychiatry 76, 58–63 (2005)
Article
Google Scholar
Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr., et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002)
Article
Google Scholar
Grieve, R., Roberts, J., Wright, M., Sweeting, M., De Angelis, D., Rosenberg, W., Bassendine, M., Main, J., Thomas, H.: Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55, 1332–1338 (2006)
Article
Google Scholar
Lamers, L.M., Bouwmans, C.A.M., van Straten, A., Donker, M.C.H., Hakkaart, L.: Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 15, 1229–1236 (2006)
Article
Google Scholar
Longworth, L., Bryan, S.: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 12, 1061–1067 (2003)
Article
Google Scholar
Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V., Shiffman, M., Reindollar, R., et al.: PegInterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958–965 (2001)
Article
Google Scholar
Mara, C.A., Woolcott, J.C., Kopec, J.A., Shojania, K., Offer, R., Brazier, J.E., Esdaile, J.M., Anis, A.H.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)
Article
Google Scholar
Michaels, J.A., Campbell, W.B., Brazier, J.E., Macintyre, J.B., Palfreyman, S.J., Ratcliffe, J., Rigby, K.: Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). Health Technol. Assess. 10(13), 1–196 (2006)
Google Scholar
National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal. NICE, London (2004)
Google Scholar
Pickard, S.A., Wang, Z., Walton, S.M., Lee, T.A.: Are decisions using cost-utility analyses robust to the choice of SF-36/SF-12 preferenced-based algorithm? BMC Health Qual. Life Outcomes 3, 1–9 (2005)
Article
Google Scholar
Stavem, K., Frøland, S.S., Hellum, K.B.: Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual. Life Res. 14, 971–980 (2005)
Article
Google Scholar
Tidermark, J., Bergström, G., Svensson, O., Törnkvist, H., Ponzer, S.: Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fracture. Qual. Life Res. 12(8), 1069–1079 (2003)
Article
Google Scholar
Tsuchiya, A., Brazier, J., Roberts, J.: Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J. Health Econ. 25, 334–346 (2006)
Article
Google Scholar
van den Hout, W.B., de Jong, Z., Munneke, M., Hazes, JMW., Breedveld, F.C., Vliet Vlieland, T.P.M.: Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. Arthritis Rheum. 53, 39–47 (2005)
Article
Google Scholar
van Stel H.F., Buskens, E.: Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual. Life Outcomes 4, 1–9 (2006)
Article
Google Scholar
Xie, F., Li, S.C., Luo, N., Lo, N.N., Yeo, S.J., Yang, K.Y., Fong, K.Y., Thumboo, J.: Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis Rheum. 57(6), 1043–1049 (2007)
Article
Google Scholar
Wee, H.L., Machin, D., Loke, W.C., Li, S.C., Cheung, Y.B., Luo, N., Feeny, D., Fong, K.Y., Thumboo, J.: Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health 10(4), 256–265 (2007)
Article
Google Scholar
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., UK Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1–113 (2006)
Google Scholar